Table 2.
Allogeneic stem cell transplantation with ongoing highly active anti-retroviral therapy (HAART).
| CD4+ count/µl | HIV load cop/ml | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference | Patient age and gender | Disease | before transplantation | Graft (CD34+ cells/kg) | Conditioning regimen | Day of engraftment | GVHD prophylaxis | HAART | Effect on HIV | Follow-up | |
| Schlegel et al. 2000 [32] | 34 male | CML | NR | 2 × 103 | MRD (NR) | BSN (16 × 1 mg/kg) CPM (2 × 60 mg/kg) | +17 | CsA MTX | DDI, d4T | Rebound ongoing HAART (day +90) | 353 days |
| Kang et al. (2002) [35] | (1) 42 male (2) 31 male | (1) AML (2) B-NHL | (1) 200 (2) 81 | (1) 494 (2) < det. | MRD (16·99 × 106) Both gene modified | CPM (60 mg/kg) FLUD (25 mg/m2) | NR | CsA | (1) IDV, d4T, 3TC (2) NFV, ABC, 3TC discont. day -7 | (2) Rebound after discont. HAART (day +60) | (1) 24 months (2) Died 12 months (relapse) |
| Sora et al. (2002) [36] | 33 female | AML | 294 | < det. | MRD (4·5 × 106) | BSN (16 × 1 mg/kg) CPM (2 × 60 mg/kg) | +9 | CsA | D4T, 3TC, IDV Discont. +5 until +14 (vomiting) | Rebound after discont. HAART (day +42) | 39 months |
| Shamansky et al. (2004) [67] | 47 male | AML | NR | NR | MRD (2·27 × 106) | FLUD (150 mg/m2) MLP (140 mg/m2) | +16 | CsA, MTX | NR | None | 250 days |
| Tomonari et al. (2005) [33] | 23 female | ALL | 72 | < det. | 1st MUD cord blood HLA-B/DR mismatch (0·7 × 105) 2nd +40 MUD one-locus Mismatch at HLA-DR (0·46 × 105) | 1st TBI (12 Gy) CPM (120 mg/kg) 2nd FLUD (3 × 40 mg/m2) | +27 | CSA MTX | d4T, 3TC, EFV Discont. days 0–28 | Rebound after discont. HAART (day +33) | 15 months |
| Binaghi et al. (2006) [68] | 31 male | AA | 383 | < 50 | Syngeneic (11·7 × 106) | CPM (4 × 5000 mg/day) | +11 | None | AZT, 3TC, EFV | None | 10 months |
| Wolf et al. (2007) [37] | 34 male | AA | 192 | < 400 | MUD (7·0 × 106) | FLUD (4 × 30 mg/m2) CPM (2 × 60 mg/kg) | +18 | ATG, CsA, MTX | ABC, 3TC, SQV Discont. 0–34 | Rebound after discont. HAART CNS reactivation | 8 months |
| Avettand-Fenoel et al. (2007) [39] | 17 male | AML | NR | < det. | MUD (NR) | IDA, FLUD, ARA-C | +19 | CsA, ATG | NR Discont. 114–134 | HIV-DNA negative Rebound after discont. HAART | Died +191 (infection) |
| Bryant & Milliken (2008) [34] | 34 male | PEL | NR | NR | MRD (2·38 × 106) | MLP (140 mg/m2), FLUD (5 × 30 mg/m2) | +13 | FK506, sirolimus, MTX | LPV, RTV, TDF, 3TC | none | 31 months |
| Woolfrey et al. (2008) [50] | (1) 39 male (2) 33 male | (1 and 2) AML | (1) 262 (2) 287 | (1 and 2) < det. | (1) MUD (4·58 × 106) (2) MUD (10·63 × 106) | (1 and 2) FLUD (90 mg/m2), TBI (200 cGy) | NR | (1 and 2) CsA, MMF | (1) EFV, ABC, TDF (2) EFV, ABC, 3TC | (1) HIV-DNA negative +56 (2) None | (1) Died +301 (relapse) (2) > 180 days |
| Hamnadani et al. (2009) [69] | (1–3) 39– 55 | (1) AML (2–3) B-NHL | (1–3) 189–457 | (1–2) < det. (3) 814 | (1) MRD, 2–3.) MUD (NR) | FLUD (30 mg/m2), BSN (8 × 0·8 mg/kg) | NR | MTX, MMF | NR | (1–2) None (3) increased viral load on +252 | (1–3) Median 375 days |
| Hütter et al. (2009) [63]; Hütter & Thiel (2010) [64] | 40 male | AML | 415 | < det. | 1st MUD (2·3 × 106) 2nd MUD (2·1 × 106) | 1st m-AMSA (4 × 100 mg/m2), FLUD (4 × 30 mg/m2), ARA-C (4 × 2000 mg/ m2), CPM (60 mg/kg), TBI (4 Gy) 2nd TBI (200 cGy) | +13 | 1st ATG, CsA, MMF 2nd CsA | EFV, FTC, TDF Discont. on day 0 | HAART discont. on day 0, no rebound | 42 months |
| Polizzotto et al. (2007; 2010) [38,70] | (1) 38 male (2) 41 male (3) 24 male | (1) MDS (2) AML (3) T-ALL | (1) 58 (2) 275 (3) 204 | (1–3) < det. | (1) MUD (NR) (2) MRD (NR) (3) MUD (NR) | (1 and 2) CPM (120 mg/kg), TBI (13·2 Gy) (3) ETP (60 mg/kg), TBI (13·2. Gy) | (1) +48 (2) +21 (3) +25 | (1) CsA (2 and 3) NR | (1) d4T, 3TC, TDF discont. days 0–365 (2) FTC, TDF, FosAPV (3) TDF, RTV, FosAPV | (1) Rebound on +30 after HAART discont. (2 and 3) None | (1) Died +730 (renal failure) (2) Died +78 (sepsis) (3) Died +105 (relapse) |
| Kamp et al. (2010) [49] | 34 male | AA | NR | NR | MUD (NR) | CPM, FLUD | NR | NR | NR discont. days 0–34 | Rebound after HAART discont. | +384 |
3TC, lamivudine; AA, aplastic anaemia; ABC, abacavir; ALL, acute lyphoblastic leukaemia; AML, acute myeloid leukaemia; ARA-C, cytarabine; ATG, anti-thymocyte globulin; AZT, zidovudine; BSN, busulfan; B-NHL, B-non-Hodgkin's lymphoma; BSN, busulphan; CML, chronic myeloid leukaemia; CPM, cyclophosphamide; CsA, cyclosporine A; DDI, didanosine; d4T, stavudine; EFV, efavirenz; FTC, emtricitabine; ETP, etoposide; FLUD, fludarabine; FosAPV, fosamprenavir; FT506, tacrolimus; IDA, idarubicin; HIV, human immunodeficiency virus; IDV, indinavir; LPV, lopinavir; m-AMSA, amsacrin; MDS, myelodysplastic syndrome; MLP, melphalan; MMF, mycophenolate mofetil; MRD, matched related donor; MTX, methotrexate; MUD, matched unrelated donor; NFV, nelfinavir; NR, not reported; PEL, HIV-related primary effusion lymphoma; RTV, ritonavir; SQV, ritonavir-boosted saquinavir; SYN, syngeneic donor; TBI, total body irradiation; TDF, tenofovir.